TickerFacts.

Fate Therapeutics Inc (FATE): Revenue

Annual figures by period end, from SEC filings.

$6.65M
Year ended 2025-12-31
$6.49M
Trailing 12 months to 2026-06-30
-59.0%
3-year compound annual growth
-26.7%
5-year compound annual growth
$96.30M2016-12-31: $4.40M2017-12-31: $4.11M2018-12-31: $4.74M2019-12-31: $10.68M2020-12-31: $31.43M2021-12-31: $55.85M2022-12-31: $96.30M2023-12-31: $63.53M2024-12-31: $13.63M2025-12-31: $6.65M$6.65M
2016-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$6.65M-51.2%2026-02-26, From 2025-01-01
2024-12-31$13.63M-78.5%2026-02-26, From 2024-01-01
2023-12-31$63.53M-34.0%2025-03-05, From 2023-01-01
2022-12-31$96.30M+72.4%2024-02-26, From 2022-01-01
2021-12-31$55.85M+77.7%2023-02-28, From 2021-01-01
2020-12-31$31.43M+194.3%2023-02-28, From 2020-01-01
2019-12-31$10.68M+125.3%2022-02-28, From 2019-01-01
2018-12-31$4.74M+15.4%2021-02-24, From 2018-01-01
2017-12-31$4.11M-6.7%2020-03-02, From 2017-01-01
2016-12-31$4.40Mn/a2019-03-05, From 2016-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Fate Therapeutics Inc (FATE)2025-12-31$6.65M-51.2%
DBV Technologies S.A. (DBVT)2025-12-31$5.64M+35.8%
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$5.20M+12.5%
Curis Inc (CRIS)2025-12-31$9.44M-13.4%
Prime Medicine, Inc. (PRME)2025-12-31$4.63M+55.3%
Taysha Gene Therapies, Inc. (TSHA)2025-12-31$9.77M+17.3%
Ocugen, Inc. (OCGN)2025-12-31$4.41M+8.8%
Alpha Cognition Inc. (ACOG)2025-12-31$10.22Mn/a
TScan Therapeutics, Inc. (TCRX)2025-12-31$10.32M+266.7%

Compare FATE, DBVT, ZEOX, CRIS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗